Transaction in Own Shares

BioPharma Credit plc

(the "Company")

TRANSACTION IN OWN SHARES

BioPharma Credit PLC (the "Company") announces that on 7 July 2022 it purchased the following number of its ordinary shares of US$0.01 each on the London Stock Exchange through J.P. Morgan Securities plc into treasury.

Ordinary Shares: BPCR LN

Date of purchase: 7 July 2022

Number of ordinary shares purchased: 470,000

Lowest price per share: $0.938

Highest price per share: $0.940

Trading venue: London Stock Exchange

Aggregate volume per date per trading venue: 470,000

Weighted average price per day per trading venue: $0.9399

Following the above transaction, the Company holds 1,106,011 of its ordinary shares in treasury and has 1,372,826,056 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,372,826,056. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

[email protected]

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24